President Donald Trump signed an order Monday limiting core childhood vaccine recommendations to 11

https://youtu.be/H_RititNE8U

Sanofi is rated a Buy, with ~33.5% upside to €99.5 fair value (or $57 for SNY ADRs), resulting from

This article is part of our monthly series where we highlight five large-cap, relatively safe, divid

Nurix Therapeutics, Inc. (Nasdaq: NRIX), a clinical-stage biopharmaceutical company focused on the d

Sanofi's MenQuadfi approved in the EU for use in infants from age six weeks against invasive meningo

Sanofi (NASDAQ: SNY - Get Free Report) has been assigned a consensus recommendation of "Hold" from t

SNY beats on Q2 earnings and sales as Dupixent tops euro 5B in quarterly sales for the first time. T

Sanofi NASDAQ: SNY raised its 2026 outlook after reporting double-digit second-quarter sales and ear

The company now expects 2026 sales to grow by around 10% excluding currency changes, with business e

Sanofi on Thursday raised its full-year sales forecast on the ​back of strong demand for blockbuster

Bank of New York Mellon Corp grew its position in Sanofi (NASDAQ: SNY) by 7.8% in the undefined quar

Add the effect of stock buybacks to the dividend, and you're looking at a total yield approaching 11

Cetera Investment Advisers increased its stake in Sanofi (NASDAQ: SNY) by 13.5% in the undefined qua

The drugmaker said efficacy and safety data didn't support further development of the drug, amliteli

Sanofi today announced discontinuation of clinical development of amlitelimab, an OX40-ligand monocl

Sanofi evolves its Executive Committee to support its next strategic chapter Paris, July 21, 2026. S

I identify dividend stocks and REITs that could protect investors from AI bubble risks, geopolitics,

PARIS & LONDON--(BUSINESS WIRE)-- #DrugDiscovery--Aqemia, the drug invention company combining gener

All three can be bought on the dip.

Kalshi is expanding into biotech with contracts on FDA drug approvals from Sanofi and Gilead, as cri

Sanofi's subcutaneous Sarclisa Escena approved in the US as first anticancer treatment administered

The U.S. Food ​and Drug ‌Administration said on Friday ​it has ​approved Sanofi's blood ⁠cancer drug

The European Commission said on Wednesday ​it would seek feedback ‌on commitments offered by French

AbbVie will acquire Apogee for $10.9 billion, adding late-stage immunology and asthma assets to its

Stocks That Hit 52-Week Lows On Monday

Stocks That Hit 52-Week Highs On Friday

Stocks That Hit 52-Week Highs On Thursday

Stocks That Hit 52-Week Highs On Friday

Stocks That Hit 52-Week Highs On Friday

Stocks That Hit 52-Week Highs On Thursday

Stocks That Hit 52-Week Highs On Tuesday

Could European Funds Offer An Opportunity Now?

3 ADR ETFs Your Broker Forgot to Mention